A new international study reveals a possible connection between GLP1 receptor agonists—used in drugs like Ozempic—and ...

Eli Lilly (NYSE: LLY) stock jumped over 14% on Thursday, powered by highly promising Phase 3 results for orforglipron, an ...

Most Wall Street stocks were little changed and the dollar ticked up on Thursday as investors took some heart from trade ...

Lilly's weight-loss drug trial shows promising results, propelling stock up 14.36%. Goldman Sachs predicts potential $23.5B in sales by 2035.